Study	O
sample	O

Patients	O
were	O
included	O
if	O
they	O
had	O
acute	O
respiratory	O
syndrome	O
and	O
a	O
definitive	O
diagnosis	O
of	O
COVID	O
-	O
19	O
,	O
made	O
based	O
on	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
chest	O
computed	O
tomography	O
scan	O
findings	O
from	O
an	O
undisclosed	O
teaching	O
hospital	O
.	O

The	O
name	O
of	O
the	O
teaching	O
hospital	O
was	O
hidden	O
due	O
to	O
blind	O
peer	O
-	O
review	O
protocol	O
.	O

Patients	O
consecutively	O
were	O
recruited	O
between	O
May	O
9th	O
,	O
2020	O
and	O
June	O
9th	O
,	O
2020	O
.	O

Inclusion	O
criteria	O
included	O
being	O
over	O
18	O
years	O
of	O
age	O
,	O
possessing	O
a	O
PCR	O
-	O
confirmed	O
COVID	O
-	O
19	O
diagnosis	O
,	O
involvement	O
of	O
>	O
than	O
30	O
%	O
of	O
both	O
lungs	O
(	O
ground	O
-	O
glass	O
opacity	O
)	O
in	O
high	O
-	O
resolution	O
computed	O
tomography	O
(	O
HRCT	O
)	O
(	O
confirmed	O
by	O
two	O
radiologists	O
)	O
,	O
O2	O
saturation	O
(	O
satO2	O
)	O
of	O
<	O
90	O
%	O
,	O
and	O
a	O
lack	O
of	O
adequate	O
response	O
to	O
initial	O
treatment	O
including	O
at	O
least	O
both	O
one	O
antiviral	O
and	O
one	O
chloroquine	O
-	O
class	O
drug	O
.	O

Exclusion	O
criteria	O
,	O
in	O
addition	O
to	O
an	O
age	O
of	O
less	O
than	O
18	O
years	O
,	O
included	O
pregnancy	O
,	O
coagulation	O
disorders	O
(	O
such	O
as	O
hemophilia	O
,	O
Von	O
Willebrand	O
disease	O
,	O
other	O
clotting	O
factor	O
deficiencies	O
)	O
,	O
history	O
of	O
hypersensitivity	O
to	O
IVIg	O
,	O
advanced	O
heart	O
failure	O
(	O
defined	O
as	O
a	O
left	O
ventricular	O
ejection	O
fraction	O
less	O
than	O
35	O
%	O
)	O
,	O
pulmonary	O
fibrosis	O
/	O
history	O
of	O
lung	O
surgery	O
,	O
and	O
the	O
presence	O
of	O
either	O
sarcoidosis	O
or	O
tuberculosis	O
(	O
that	O
may	O
interfere	O
with	O
an	O
accurate	O
estimation	O
of	O
the	O
severity	O
of	O
pulmonary	O
interference	O
by	O
COVID	O
-	O
19	O
)	O
.	O

Inadequate	O
response	O
to	O
initial	O
treatment	O
was	O
defined	O
as	O
the	O
lack	B-UnclearOutcome
of	I-UnclearOutcome
improvement	I-UnclearOutcome
of	I-UnclearOutcome
dyspnea	I-UnclearOutcome
,	I-UnclearOutcome
fever	I-UnclearOutcome
,	I-UnclearOutcome
and	I-UnclearOutcome
hypoxemia	I-UnclearOutcome
(	I-UnclearOutcome
satO2	I-UnclearOutcome
less	I-UnclearOutcome
than	I-UnclearOutcome
90	I-UnclearOutcome
%	I-UnclearOutcome
)	I-UnclearOutcome
,	I-UnclearOutcome
as	I-UnclearOutcome
well	I-UnclearOutcome
as	I-UnclearOutcome
the	I-UnclearOutcome
need	I-UnclearOutcome
for	I-UnclearOutcome
oxygenation	I-UnclearOutcome
to	I-UnclearOutcome
maintain	I-UnclearOutcome
satO2	I-UnclearOutcome
above	I-UnclearOutcome
90	I-UnclearOutcome
%	I-UnclearOutcome
after	B-TimeFrame
48	I-TimeFrame
h	I-TimeFrame
of	I-TimeFrame
commencing	I-TimeFrame
treatment	I-TimeFrame
.	O

Conclusions	O

The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
the	O
administration	O
of	O
IVIg	O
in	O
patients	O
with	O
severe	O
COVID	O
-	O
19	O
infection	O
who	O
did	O
not	O
respond	O
to	O
initial	O
treatments	O
could	O
improve	O
clinical	B-UnclearOutcome
outcomes	I-UnclearOutcome
and	O
thus	O
reduce	O
mortality	B-UnclearOutcome
rates	I-UnclearOutcome
.	O

Regarding	O
high	O
price	O
of	O
IVIg	O
,	O
we	O
suggest	O
that	O
it	O
should	O
be	O
considered	O
in	O
patients	O
with	O
>	O
30	O
%	O
involvement	B-UnclearOutcome
of	I-UnclearOutcome
lungs	I-UnclearOutcome
in	I-UnclearOutcome
lung	I-UnclearOutcome
CT	I-UnclearOutcome
scan	I-UnclearOutcome
,	O
whom	O
their	O
dyspnea	O
do	O
not	O
improve	O
with	O
standard	O
treatment	O
,	O
those	O
with	O
persistent	O
satO2	B-UnclearOutcome
under	O
90	O
%	O
,	O
and	O
those	O
who	O
develop	O
aggravation	O
of	O
lung	O
involvement	O
in	O
serial	O
lung	O
CT	O
scans	O
,	O
especially	O
in	O
younger	O
adults	O
.	O

